| Date | Title | Description |
| 18.08.2025 | Hatteras Venture Partners: Over $200 Million Raised For Two Healthcare Funds | Hatteras Venture Partners has announced the final closings of Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I, LP (HOF I), securing over $200 million in capital commitments from limited partners. This milestone coinc... |
| 25.09.2024 | Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress | KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease
KT-621 demonstrated strong degradation of STAT6 in human sensory neurons resulting in inhibition of I... |
| 31.07.2024 | Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 | Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report... |
| 09.07.2024 | Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day | WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today annou... |
| 08.07.2024 | Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy | WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today annou... |
| 08.07.2024 | Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy | WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today annou... |
| 01.06.2024 | Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting | KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML
Evidence of target engagement and potent upregulation of p53 pathway biomarke... |
| 08.03.2024 | Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting | - |
| 07.12.2023 | Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment ... | - |
| 27.10.2023 | Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Pay... | - |
| 27.10.2023 | Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Pay... | The dosing of the first patient in the Phase 2 Atopic Dermatitis (AD) clinical trial is expected later this quarter
WATERTOWN, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceut... |
| 09.06.2023 | Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Model... | A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical models of ALL and AML
/EIN News/ -- WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- K... |
| 22.05.2023 | Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer | /EIN News/ -- WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degra... |
| 16.12.2021 | A-Alpha Bio Partners with Kymera Therapeutics to Discover Novel Interactions for Molecular Glue Discovery | “Kymera and A-Alpha share a commitment to innovation and to expanding the potential of targeted protein degradation by unlocking new ligases and new previously undruggable targets." -David Younger, PhD, Co-Founder and CEO of A-Alpha Bi... |
| 12.03.2020 | Kymera Therapeutics Announces $102 Million Series C Financing | Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by... |
| 12.03.2020 | Kymera Therapeutics Raises $102M in Series C Financing | Kymera Therapeutics Inc., a Cambridge, Mass.-based biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, closed a $102m Series C financing.
The round was led by Biotech... |
| 12.03.2020 | Kymera Therapeutics Scoops Up $102M Series C |
CAMBRIDGE, MA, Kymera Therapeutic today announced the closing of a $102 million Series C financing.
>> Click here for more funding data on Kymera Therapeutics
>> To export Kymera Therapeutics funding data to PDF and Excel, c... |
| 19.07.2019 | Seer adds ex-FDA chief Mark McClellan to the board; Hercules Capital makes it official for new CEO Scott Bluestein | Mark McClellan
→ On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its boar... |
| 14.11.2018 | Term Sheet — Wednesday, November 14 | SOFTBANK
Good morning Term Sheet readers. This is Lucinda filling in for Polina until Friday. Please send all deals to lucinda.shen@fortune.com.
Paid Content How can you protect what you can't see? From ExtraHop
That comes after Softbank co... |
| 13.11.2018 | Kymera Therapeutics Raises $65M in Series B Financing | Kymera Therapeutics Inc., a Cambridge, Mass.-based biotechnology company advancing targeted protein degradation to create innovative medicines for patients, completed a $65m Series B financing.
The round was co-led by 6 Dimensions Capital, ... |
| 13.11.2018 | Kymera Therapeutics Receives $65M |
CAMBRIDGE, MA, Kymera Therapeutics Inc, a biotechnology company, has closed $65 million in Series B financing.
>> Click here for more funding data on Kymera Therapeutics
>> To export Kymera Therapeutics funding data to PDF a... |
| 13.11.2018 | Kymera Therapeutics Announces $65 Million Series B | Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, announced today that it has completed a $65 million Series B financing. The financing will support the ... |
| 13.11.2018 | Kymera nets $65M to move lead protein degrader into the clinic | Kymera Therapeutics raised $65 million in series B funding that will support the clinical development of its lead protein degradation program, as well as advance its other preclinical assets. CEO Laurent Audoly kept mum on specific targets ... |
| 21.09.2018 | Ex-Cascadian chief Scott Myers lands at BioClin; Kodiak woos Genentech vet Jason Ehrlich for CMO role | Scott Myers
→ Scott Myers and Julie Eastland, two of the top execs headed out as Cascadian Therapeutics got absorbed into Seattle Genetics, have both settled at BioClin Therapeutics. Staying in familiar roles, Myers... |
| 04.04.2018 | CAR-T player Poseida marches on with $30.5M Series B; Kymera inks discovery deal with GSK | → Investors have infused $30.5 million in Series B cash into Poseida Therapeutics’ pipeline of autologous T cell and NK cell therapies. Using its gene engineering tech, the San Diego company has identified several C... |
| 09.02.2018 | CSO Bill Lundberg transitions to advisor role at CRISPR Therapeutics; Prothena loses CMO Sarah Noonberg; Sanofi vet Mark Nuttall jumps to Kymera | Bill Lundberg
→ Wrapping a three-year run marked by the first clinical trial applications for CRISPR-based therapies, Bill Lundberg is stepping down as CSO of CRISPR Therapeutics $CRSP. He will stay with the company as the... |
| 04.01.2018 | Pfizer and Arvinas sign $830M drug development deal that target proteins causing disease | So what’s attracting the big fish? There are no clinical programs tied up in any of the deals. Instead, they will be drawing on the fruits of Arvinas’s proprietary PROteolysis TArgeting Chimeras (PROTAC) platform. According to a company spo... |
| 31.10.2017 | Term Sheet — Tuesday, October 31 | DEAD AND GONE
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
The top 5 in the startup graveyard (ranked by valuation):
JAWBONE
A developer of wearable tech and portable audio devices.
Va... |
| 30.10.2017 | Kymera Therapeutics Raises $30M In Series A | Kymera Therapeutics LLC today announced a $30M Series A Financing round to advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases. The company is pioneering ... |
| 30.10.2017 | Kymera Therapeutics Announces $30M Series A |
CAMBRIDGE, MA, Kymera Therapeutics LLC today announced a $30M Series A Financing round.
>> Click here for more funding data on Kymera Therapeutics
>> To export Kymera Therapeutics funding data to PDF and Excel, click here
... |
| 30.10.2017 | Kymera Therapeutics Raises $30M in Series A Financing | Kymera Therapeutics, LLC, a Cambridge, MA-based biotechnology company, raised $30M in Series A financing.
The round was led by Atlas Venture, which co-founded, seeded, and incubated the company, along with Lilly Ventures and Amgen Ventures.... |
| - | Pfizer and Arvinas sign $830M drug development deal that target proteins causing disease | New Haven, Connecticut-based Arvinas has signed a new deal with Pfizer that could be worth up to $830 million.
Announced Thursday, it follows in the footsteps of other multiyear, multimillion-dollar deals struck with Merck and Genentech, ma... |
| - | Targeted protein degradation: treating inflammatory diseases in a new way | Targeted protein degradation, or the ability to harness the body’s protein recycling machinery to degrade disease-causing proteins, is emerging as one of the most exciting new therapeutic modalities with broad potential to effectively treat... |
